Overall survival for amivantamab plus lazertinib versus osimertinib as first-line treatment in Asian participants with EGFR-mutant advanced NSCLC: A MARIPOSA subset analysis - PubMed
7 days ago
- #NSCLC
- #Asian patients
- #EGFR-mutated
- Amivantamab plus lazertinib significantly improved overall survival (OS) compared to osimertinib in Asian patients with EGFR-mutated advanced NSCLC.
- Median OS was not reached for amivantamab-lazertinib versus 38.4 months for osimertinib (HR, 0.74; nominal P = 0.026).
- At 36 months, 61% of patients in the amivantamab-lazertinib group were alive compared to 53% in the osimertinib group.
- The safety profile of amivantamab-lazertinib was consistent with the overall population.
- This is the first regimen to show survival improvement in Asian patients with EGFR-mutated advanced NSCLC.